Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

18 juil. 2019 16h12 HE | Source: Ascendis Pharma A/S

Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for Initiation of a Global Phase 2 Trial for TransCon™ CNP in Children with Achondroplasia

COPENHAGEN, Denmark, July 18, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address significant unmet...
19 juin 2019 08h30 HE | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces R&D Day on June 26 to Review Endocrinology Rare Disease Pipeline and Introduce Oncology Programs

– Continued progress of all three global endocrinology rare disease programs – – Validation of TransCon™ platform in phase 3 heiGHt Trial paves way for new therapeutic areas, including oncology – ...
30 mai 2019 16h02 HE | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Reports First Quarter 2019 Financial Results

– Continued execution of global endocrinology rare disease programs, following validation of TransCon™ platform in phase 3 heiGHt Trial – – R&D Day on June 26 to feature endocrinology and...
20 mai 2019 07h30 HE | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Preliminary Data from Single Arm Phase 3 fliGHt Trial Demonstrated TransCon™ hGH was Safe and Well-Tolerated in Pediatric Subjects Previously Treated with Daily Growth Hormone

- Provides real-world experience for switching pediatric growth hormone deficiency subjects one to 17 years old from daily growth hormone to once-weekly TransCon hGH - - Data included...
16 mai 2019 08h00 HE | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces First Quarter 2019 Financial Results and Business Update Conference Call on May 30

COPENHAGEN, Denmark, May 16, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
07 mai 2019 16h02 HE | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Participation in the Bank of America Merrill Lynch 2019 Healthcare Conference

COPENHAGEN, Denmark, May 07, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
24 avr. 2019 17h26 HE | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Presentations Related to Rare Disease Endocrinology Pipeline at Upcoming Medical Conferences

COPENHAGEN, Denmark, April 24, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical...
03 avr. 2019 16h01 HE | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Reports Full Year 2018 Financial Results

– Rare disease endocrinology pipeline continues to advance, with significant 2019 milestones anticipated – – Phase 3 heiGHt Trial results showcase potential of TransCon™ technologies and support...
27 mars 2019 17h00 HE | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Year-End 2018 Financial Results and Business Update Conference Call on April 3

COPENHAGEN, Denmark, March 27, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical...
25 mars 2019 14h00 HE | Source: Ascendis Pharma A/S

Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life

COPENHAGEN, Denmark, March 25, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical...

Page précédente